Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + relatlimab with platinum-pemetrexed chemotherapy versus pembrolizumab with platinum-pemetrexed chemotherapy in first-line PD-L1-positive non-squamous advanced NSCLC
jRCT2051240173Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of nivolumab, relatlimab, pembrolizumab, pemetrexed, carboplatin and 1 more in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival in participants with PD-L1 1% to 49%. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2051240173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240173.